Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Accounting Standards: International Financial Reporting Standards (IFRS)
Business Overview: uniQure is a biopharmaceutical company focused on developing gene therapies for liver-based, cardio/metabolic, and central nervous system diseases. Its lead product, Glybera, received marketing authorization in the European Union in October 2012 for the treatment of lipoprotein lipase deficiency (LPLD). The company operates manufacturing facilities in Amsterdam and Lexington, Massachusetts.
Key Financial Metrics
| Metric (€ in thousands) | 2014 | 2013 |
|---|---|---|
| Total Revenues | 4,685 | 2,943 |
| Research & Development Expenses | (33,932) | (13,182) |
| Selling, General & Administrative Expenses | (11,167) | (11,628) |
| Net Loss | (37,040) | (26,820) |
| Cash and Cash Equivalents (Year End) | 53,219 | 23,810 |
| Total Debt | 17,270 | 7,864 |
| Accumulated Deficit | (181,081) | (144,041) |
Revenue Composition (2014): License revenues of €883,000 and Collaboration revenues of €3,802,000. No product sales revenue was generated.
Debt Structure: As of December 31, 2014, the company had €16.4 million in outstanding borrowings under a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. Principal repayments are scheduled to begin in January 2016.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 59% to €4.7 million, driven by a 101% increase in license revenue (amortization of Chiesi upfront payments) and a 52% increase in collaboration revenue (reimbursements for hemophilia B development).
- Expense Surge: Research and development (R&D) expenses increased 157% to €33.9 million. This was primarily due to the expansion of the hemophilia B program, the build-out of the Lexington manufacturing facility, and €6.3 million in share-based compensation related to the 4D Molecular Therapeutics collaboration.
- Net Loss Expansion: Net loss increased 38% to €37.0 million, reflecting the significant rise in R&D costs despite revenue growth.
- Liquidity Improvement: Cash and cash equivalents more than doubled to €53.2 million, largely due to net proceeds of €62.0 million from the February 2014 Initial Public Offering (IPO) and an additional €7.2 million from the amended Hercules loan.
- Other Gains: The company recorded a net gain of €5.8 million in "Other gains/losses," compared to a loss of €0.45 million in 2013, primarily due to favorable foreign exchange movements between the Euro and the U.S. Dollar.
Guidance, Outlook, and Risks
Outlook and Capital Needs: The company expects to incur significant losses over the next several years. Management anticipates expenses will increase substantially to fund clinical trials for AMT-060 (hemophilia B), post-approval trials for Glybera, and the commercialization of Glybera in the EU. The company believes its cash position, combined with anticipated proceeds from a collaboration with Bristol-Myers Squibb (BMS) signed in April 2015, will fund operations for at least the next 12 months.
Key Developments:
- BMS Collaboration: Entered into a strategic agreement with BMS for cardiovascular gene therapies, including an upfront payment of $50 million and potential milestone payments totaling up to $254 million for the lead asset.
- Glybera Commercialization: First patient treatment in the EU is expected in mid-2015 via collaborator Chiesi. A price of €41,000 per vial was established in Germany.
- Manufacturing: Completed build-out of the Lexington, MA facility; GMP validation expected in H1 2015.
Material Risks:
- Regulatory Uncertainty: Glybera approval in the EU was granted under "exceptional circumstances" and is subject to annual reassessment. FDA approval in the U.S. is not guaranteed and may require additional clinical trials.
- Manufacturing Challenges: The company encountered consistency and stability issues with the Glybera manufacturing process in late 2014, requiring an improved process and comparability studies.
- Internal Controls: The company identified three material weaknesses in its internal control over financial reporting for 2014, which it is actively remediating.
- Dependence on Third Parties: Reliance on Chiesi for EU commercialization and BMS for cardiovascular development creates execution risk.
Investor Verification Checklist
- BMS Deal Closing: Verify the closing of the Bristol-Myers Squibb collaboration, including receipt of the $50 million upfront payment and equity investment, as this is critical for near-term liquidity.
- Glybera Launch Status: Monitor the actual timeline for the first patient treatment in the EU and the outcome of the German Federal Joint Committee (G-BA) assessment on pricing and reimbursement.
- Manufacturing Resolution: Confirm the successful submission and regulatory acceptance of the comparability studies for the improved Glybera manufacturing process.
- Internal Control Remediation: Review future filings to confirm the remediation of the three material weaknesses in internal controls over financial reporting.
- Debt Covenants: Monitor compliance with the Hercules loan covenants, particularly the minimum cash balance requirements and restrictions on additional indebtedness.